2-甲基喹啉-8-醇盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-甲基喹啉-8-醇盐酸盐
• 英文名称: hydron;2-methylquinolin-8-ol;chloride
• 化学式: C10H10ClNO
• 分子量: 195.64
• InChiKey: JEQJTJSUPMXLFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.67
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  33.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] NO-RELEASING NITROOXY-CHROMENE CONJUGATES<br/>[FR] CONJUGUÉS NITROOXY-CHROMÈNE À LIBÉRATION DE NO
  申请人：EUCLISES PHARMACEUTICALS INC

  公开号：WO2015109011A1

  公开（公告）日：2015-07-23

  The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1 ) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound o Formula (I); and methods useful for healing wounds, preventing and treating cancer and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (1).

  本发明提供了NO释放的硝基氧烷基连接的香豆素共轭物，其具有如下式（1）的结构，其中R1、R2、R3、R4、X和L如详细描述中所定义；包含至少一种Formula（I）化合物的药物组合物；以及使用Formula（1）化合物有益于愈合伤口、预防和治疗癌症以及治疗日光性角化症、囊性纤维化和痤疮的方法。
• NO-RELEASING NITROOXY-CHROMENE CONJUGATES
  申请人：EUCLISES PHARMACEUTICALS, INC.

  公开号：US20160340330A1

  公开（公告）日：2016-11-24

  The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound o Formula (I); and methods useful for healing wounds, preventing and treating cancer and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (1).

  本发明提供了NO释放的硝基氧烷基连接的色酮共轭物，其具有如下式（1）的结构，其中R1、R2、R3、R4、X和L如详细描述中所定义；包含至少一种Formula（I）化合物的药物组合物；以及使用Formula（1）化合物有益于愈合伤口、预防和治疗癌症以及治疗光老化性角化症、囊性纤维化和痤疮的方法。
• [EN] NO-RELEASING NONOATE(OXYGEN-BOUND)CHROMENE CONJUGATES<br/>[FR] CONJUGUÉS DE NONOATE(LIÉ À L'OXYGÈNE)CHROMÈNE LIBÉRANT DE L'OXYDE NITRIQUE
  申请人：EUCLISES PHARMACEUTICALS INC

  公开号：WO2015109014A1

  公开（公告）日：2015-07-23

  The present invention provides NO-releasing NONOate(oxygen bound)chromene conjugates, having the structure of Formula (I): wherein Z, R1, R2, R3, R4, R5, R6, and R7 are as defined in the detailed description; pharmaceutical compositions comprising at least one compound of Formula (I); and methods useful for healing wounds, preventing and treating cancer, or treating actinic keratosis, cystic fibrosis, or acne, using a compound of Formula (I).

  本发明提供了释放NO的NONOate（氧结合）香豆素共轭物，其具有如下结构（I）的结构：其中Z、R1、R2、R3、R4、R5、R6和R7如详细描述中所定义；包括至少一种化合物的制药组合物（I）；以及使用化合物（I）有益于愈合伤口、预防和治疗癌症，或治疗光老化性角化症、囊性纤维化或痤疮的方法。
• NO-RELEASING GUANIDINE-CHROMENE CONJUGATES
  申请人：Euclises Pharmaceuticals, Inc.

  公开号：US20150197500A1

  公开（公告）日：2015-07-16

  The present disclosure provides NO-releasing guanidine-chromene conjugates, having the structure of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 10 , and L are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds of Formula (I); and methods useful for healing wounds, preventing and treating cancer, or treating actinic keratosis, cystic fibrosis, acne, or a disease mediated by arginine deficiency using a compound of Formula (I).

  本公开提供NO释放的胍基-色酮共轭物，具有以下结构的化学式(I)：其中R1、R2、R3、R4、R10和L如详细说明中定义；包含至少一种化合物的药物组合物的制剂；以及使用化合物(I)治愈伤口、预防和治疗癌症、或治疗日光性角化症、囊性纤维化、痤疮或由精氨酸缺乏介导的疾病的有用方法。
• [EN] IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS<br/>[FR] DERIVES D'IMIDAZOLINE UTILISES COMME LIGANDS DU RECEPTEUR ADRENERGIQUE ALPHA-1A
  申请人：GLAXO GROUP LTD

  公开号：WO2000066563A1

  公开（公告）日：2000-11-09

  Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Formula (i) wherein R?2, R3, R4 and R5¿ are independently H, halogen, -OH, -C¿1-3?alkyl, -C1-3alkoxy, -SC1-2alkyl, or -CF3, with the proviso that at least 2 of R?2, R3, R4 and R5¿ are H; R6 is H or -CH¿3; R?1 is -S(O)¿nR?7 where n is 1 or 2, -S(O)¿2NHR?8, -C(O)R?9, -NR14R15, -C(R17)=NOR16¿, (a) or a 5,6, or 7 membered heteroalkyl or heteroaryl group optionally substituted. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

  公开了式(I)的化合物或其药学上可接受的盐或溶剂化物。式(I)中，R?2、R3、R4和R5¿独立地为H、卤素、-OH、-C¿1-3?烷基、-C1-3烷氧基、-SC1-2烷基或-CF3，但至少有2个R?2、R3、R4和R5¿为H；R6为H或-CH¿3；R?1为-S(O)¿nR?7，其中n为1或2，-S(O)¿2NHR?8，-C(O)R?9，-NR14R15，-C(R17)=NOR16¿，(a)或可选择取代的5、6或7成员杂烷基或杂芳基基团。这些化合物在治疗α-1A介导的疾病或病况，例如尿失禁方面有用。